Morgan Stanley Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Keymed Biosciences, Inc. with a HK$88.58 average price target.

Based on Keymed Biosciences, Inc.’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$213.93 million and a GAAP net loss of HK$436.39 million. In comparison, last year the company earned a revenue of HK$373.44 million and had a GAAP net loss of HK$178.5 million